Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Case Studies: Advances in Glaucoma Therapy

By: Nathan Radcliffe, MD; Jim Thimons, DO

Webinar Credits: 1

Expiration Date: Monday, December 20, 2021
Release Date: December 2018
EXPIRATION DATES:
AMA PRA CATEGORY 1 CREDIT EXPIRATION DATE: DECEMBER 31, 2019
COPE EXPIRATION DATE: DECEMBER 10, 2021

Learning Objectives

Upon completion of this activity, participants will be better able to:
Explain how novel therapeutics differ in their methods of action from other topical medications.
Evaluate the safety and efficacy of latanoprostene bunod for ocular hypertension and primary open-angle glaucoma.
Describe how a healthy eye manages intraocular pressure in contrast with an unhealthy eye.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In cooperation with Evolve Medical Education LLC, the University of Houston College of Optometry has reviewed and endorsed this course.

Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
COPE Course ID: 60201-GL
COPE Event ID: 116630

COPE EXPIRATION DATE: December 10, 2021

Faculty and Disclosures

Nathan Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie; Alcon/Novartis; Allergan; Glaukos; Baush + Lomb; Beaver Visitec; Carl Zeiss Meditec; Ellex; Endo Optiks; Equinox; Iridex; Ivantis; Lumenis; New World Medical; Ocular Science; Omeros; Reichert; Sight Science; TearScience; Speaker: Aerie; Alcon/Novartis; Allergan; Alimera; Glaukos; Baush + Lomb; Beaver Visitec; Carl Zeiss Meditec; Equinox; Iridex; Lumenis; New World Medical; Ocular Science; Reichert; Sight Science;

James Thimons, O.D., FAAO., has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker: Aerie; Alcon/Novartis; Allergan; Baush + Lomb; Carl Zeiss Meditec; Diopsys; Glaukos; InFocus; PRN; Reichert; Shire; Tear Lab;

Editorial Support Disclosure

Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch & Lomb.

Pretest

  • 12345
  • 12345

Video Resources

Next

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    Explain how novel therapeutics differ in their methods of action from other topical medications.
    Evaluate the safety and efficacy of latanoprostene bunod for ocular hypertension and primary open-angle glaucoma.
    Describe how a healthy eye manages intraocular pressure in contrast with an unhealthy eye.
Back